Join the Prostate Cancer group to help and get support from people like you.
Prostate Cancer News (Page 5)
Related terms: Cancer, Prostate, Carcinoma of Prostate
Blood Test Can Help Predict Survival From Advanced Prostate Cancer
MONDAY, Oct. 7, 2024 – A simple blood test may help doctors decide the best way to treat a man with advanced prostate cancer. A phase 3 clinical trial has shown that circulating tumor cell (CTC)...
ASTRO: Intensity-Modulated RT, Proton Beam Therapy Have Similar Outcomes in Prostate Cancer
FRIDAY, Oct. 4, 2024 – Intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) offer similar outcomes for patients with localized prostate cancer, according to a study presented...
Cancer Incidence Rates in 2021 Indicate Return to Prepandemic Levels
MONDAY, Sept. 30, 2024 – The overall incidence rates for all cancer sites and specific cancer sites returned to prepandemic levels in 2021, according to a study published online Sept. 24 in the...
No Infections Seen After Transperineal Biopsy for Prostate Cancer
MONDAY, Sept. 30, 2024 – For patients with suspicion for prostate cancer, transperineal biopsy has similar cancer detection rates as transrectal biopsy but a significantly lower risk for infection,...
Omitting Biopsy With Negative MRI Reduces Detection of Clinically Insignificant Prostate Cancer
FRIDAY, Sept. 27, 2024 – Omitting biopsy in patients with negative magnetic resonance imaging (MRI) results is associated with a significantly reduced relative risk for detecting clinically...
Men Often Confused About Prostate Cancer Screening, Survey Shows
MONDAY, Sept. 9, 2024 – A new survey finds the majority of American men believe the first step in prostate cancer screening is an invasive rectal exam by their doctor. That's not true, but mistaken...
Olaparib Monotherapy Yields Good PSA Response Rates in Prostate Cancer
MONDAY, Aug. 26, 2024 – For men with high-risk biochemically recurrent prostate cancer, olaparib monotherapy yields good prostate-specific antigen (PSA) response rates, especially among those with...
Mental Health Utilization Increased Around Time of Prostate Cancer Diagnosis
FRIDAY, Aug. 16, 2024 – There is an increase in psychotropic medication use and mental health service use around the time of prostate cancer diagnosis, according to a study published online July 3...
Pfizer and Astellas' Xtandi Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
TOKYO and NEW YORK, Nov. 16, 2023 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies...
FDA Approves Akeega (niraparib and abiraterone acetate) for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
HORSHAM, Pa., August 11, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food & Drug Administration (FDA) has approved Akeega™ (niraparib and abi...
Pfizer’s Talzenna (talazoparib) in Combination with Xtandi (enzalutamide) Receives U.S. FDA Approval for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
NEW YORK--(BUSINESS WIRE) June 20, 2023 – Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase...
FDA Approves Lynparza (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lynparza combination showed a clinically meaningful reduction in risk of disease progression or death in these patients in the Phase 3 PROpel trial First approval of a PARP inhibitor in combination...
FDA Approves Expanded Indication for Telix’s Illuccix to Include Patient Selection for PSMA-Directed Radioligand Therapy
Indianapolis, IN (United States) | 16 March 2023 – Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application...
U.S. FDA Approves Additional Indication of Nubeqa (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Nubeqa now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1 Today’s approval under the FDA’s Real-Time On...
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year...
Further information
Related condition support groups
Related drug support groups
Lupron, Lupron Depot, estradiol, Premarin, Estrace, Xtandi, docetaxel, Zytiga